Patents by Inventor Carlo De Toma

Carlo De Toma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors
    Patent number: 9889121
    Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: February 13, 2018
    Assignee: Recordati Ireland Ltd.
    Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
  • HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS
    Publication number: 20170182011
    Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 29, 2017
    Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
  • Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors
    Patent number: 9593127
    Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: March 14, 2017
    Assignee: RECORDATI IRELAND LTD.
    Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
  • HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
    Publication number: 20160185798
    Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
    Type: Application
    Filed: December 29, 2015
    Publication date: June 30, 2016
    Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
  • Spiroheterocyclic compounds as mGlu5 antagonists
    Patent number: 8580962
    Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: November 12, 2013
    Assignee: Recordati Ireland Ltd.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Davide Graziani, Carlo De Toma, Katia Dimitrova Karamfilova
  • NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS
    Publication number: 20120059015
    Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.
    Type: Application
    Filed: July 11, 2011
    Publication date: March 8, 2012
    Applicant: Recordati Ireland Ltd.
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Davide Graziani, Carlo De Toma, Katia Dimitrova Karamfilova